Press releasePRNewswire
Amgen
AMGN · NASDAQ
$438.94+$14.00 (+3.29%)TodayMarket closed ·
Prev close $424.94
Latest news
- NewsVandana Singh
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study
- Press releasePRNewswire
TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS
- NewsPiero Cingari
Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today
- NewsPiero Cingari
Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average
- Press releasePRNewswire
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
- News
10 Health Care Stocks With Whale Alerts In Today’s Session
- News
10 Health Care Stocks Whale Activity In Today’s Session
- NewsVandana Singh
Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data
- Press releasePRNewswire
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
- NewsPiero Cingari
Bitcoin Tops $80,000, S&P 500 Slips as Yields Reclaim 5%: Stock Market Today
- Press releasePRNewswire
FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
- News
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
- News
10 Health Care Stocks With Whale Alerts In Today’s Session
- Press releasePRNewswire
AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- NewsMohd Haider
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know
- NewsPiero Cingari
QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000
- NewsPiero Cingari
S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today
- NewsVandana Singh
What's Going On With Amgen Stock Tuesday?
- NewsVandana Singh
Astrazeneca Secures FDA Approval for New Breast Cancer Treatment
- Press releasePRNewswire
IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- NewsAvi Kapoor
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
- Press releasePRNewswire
AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
- Press releasePRNewswire
AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
- NewsVandana Singh
AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
- Press releasePRNewswire
TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS
- News
10 Health Care Stocks Whale Activity In Today’s Session
- News
9 Health Care Stocks Whale Activity In Today’s Session
- NewsMohd Haider
Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'
- NewsAvi Kapoor
Chubb, Toast And A Health Care Stock On CNBC’s ‘Final Trades’
- NewsPiero Cingari
Gold Jumps 4%, Dow Jones Smashes Record Highs: Stock Market Today
- News
Amgen Q2 Adj. EPS $6.29 Beats $5.62 Estimate, Sales $10.054B Beat $9.421B Estimate
- Press releasePRNewswire
AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
- NewsKaustubh Bagalkote
SpaceX Could Swing $204 Billion After Earnings
- NewsStjepan Kalinic
Two Years to Build or Pay 200% — Which US Pharma Stocks Win?
- Press releasePRNewswire
AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
- Press releasePRNewswire
/C O R R E C T I O N -- Amgen/
- NewsChris Katje
The Dow Jones Earnings Showdown: 11 Blue‑Chips Step Up This Week
- News
P/E Ratio Insights for Amgen
- Press releasePRNewswire
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
- NewsChris Katje
Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites
- Press releasePRNewswire
AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
- News
Price Over Earnings Overview: Amgen
- News
P/E Ratio Insights for Amgen
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.